We turn science
into medicine.

scroll down

Angiolutions

stops

aortic aneurysms.

An abdominal aortic aneurysm (AAA) is a local “ballooning” of the aorta – the biggest blood vessel in the human body.

AAA is a frequent disease, affecting up to 5% of the population.

AAAs are progressive in nature – that means, AAAs become larger over time and may eventually rupture.

AAA rupture is lethal
in most cases.

To date, there is no treatment to stop AAA progression.

A

bdominal

A

ortic

A

neurysm

Technology

A³ - Shield: The first device tackling the root cause of AAA

You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

Unblock content Accept required service and unblock content

Angiolutions: first device to stop AAA progression

Dr. Isabel N. Schellinger

Marius Rummel

Chief Business Officer

Dr. Uwe Raaz

About us

Angiolutions’ leadership team: Co-founders and Co-CEOs Dr. Uwe Raaz & Dr. Isabel N. Schellinger and Chief Business Officer Marius Rummel. Together, they lead a diverse, interdisciplinary team that is complemented by a board of industry veterans, top clinicians and leading researchers.

show more show less

Traction

Forbes - 30 under 30

TMC X Companies

Jörg-Vollmar-Award

MIT Technology Review

Winner MedTech Bootcamp

1st Prize World IP Day Competition

Winner START HEALTHCARE

Winner CSI Innovation Award

€2.5m EIC Accelerator grant

News

Angiolutions strengthens intellectual property protection for its early aortic aneurysm treatment: second US patent granted

October 9, 2024: Angiolutions has further expanded its patent portfolio to 16 filed patents, protecting the device in various jurisdictions.

Angiolutions announces advisory board to accelerate early-stage treatment for abdominal aortic aneurysms

July 3, 2024 – Angiolutions announces its Advisory Board, comprising industry leaders, distinguished researchers, and clinicians from world-renowned institutions.

Angiolutions wins START HEALTHCARE competition

June 18, 2024 – Angiolutions won first place in the competition START HEALTHCARE which was held at the MedtecLIVE Tradefair in Stuttgart.

Angiolutions secures €2.5 million European Innovation Council grant to fast-track its groundbreaking aneurysm treatment

July 27th, 2023, Angiolutions has been awarded the prestigious European Innovation Council (EIC) Accelerator Grant and will receive €2.5 million in non-dilutive funding for its groundbreaking treatment for early-stage abdominal aortic aneurysms.

Angiolutions wins 1st Place in
FICPI World IP Day Competition 2023

April 26, 2023: Angiolutions has won the FICPI World IP Day competition 2023, with this year's theme being "Women and IP: Accelerating Innovation and Creativity," honoring female inventors and their achievements.
The company's CEO, Dr. Isabel Schellinger, was recognized for Angiolutions' outstanding IP strategy and strong patents, which secure Angiolutions’ groundbreaking work on a minimally invasive device to treat small abdominal aortic aneurysms.

Angiolutions wins Maxis CSI Innovator Award

December 10, 2022: Angiolutions has been honored with the Maxis CSI Innovator Award, acknowledging the company's groundbreaking technology, remarkable potential for impact, robust IP strategy, and exceptional market potential in addressing abdominal aortic aneurysms.

Angiolutions receives ISO 13485 certification for its fully digital quality management system

As of February 7, 2022, Angiolutions is ISO 13485 certified. This ensures highest levels of quality and patient safety in our journey to bring the first device to treat small abdominal aortic aneurysms (AAAs) to market and to help hundred thousands of patients.

Stay in touch

receive update emails a few times a year